Mablink Bioscience
Lyon, France · Founded 2018 · $40.5M raised
- Headquarters
- Lyon
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- mablink.com
- Total Funding
- $40.5M
- Last Round
- $35.6M Series AOct 2022
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Mablink Bioscience was a French biotechnology company founded in 2018 and based in Lyon, France, developing next-generation antibody-drug conjugates (ADCs) based on its proprietary PSARlink drug-linker technology. The company's platform enabled the creation of highly potent ADCs with improved tolerability and therapeutic windows compared to earlier-generation conjugates, targeting oncology indications. Mablink raised a €31M Series A led by Sofinnova Partners and Mérieux Equity Partners before being acquired by Eli Lilly and Company in late 2023.
Summary
Mablink Bioscience is a Biotech company based in Lyon, France, founded in 2018. It has raised $40.5M in total across 2 rounds, most recently a $35.6M Series A round in Oct 2022. Investors include Sofinnova Partners, Mérieux Equity Partners and Elaia.
Funding History
Oct 2022
Sign up to see all 2 events
Funding: Seed through Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/mablink-bioscience"><img src="https://indexed.vc/api/badge/company/mablink-bioscience" alt="Mablink Bioscience on Indexed.vc" width="260" height="76" /></a>